Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005036 | 0.80 | TBXAS1 (0.54) | NPC1POLBTBXAS1CYP19A1CYP11B1 | |
| SCHEMBL12639833 | 0.78 | CYP19A1 (0.68) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL27293916 | 0.78 | ALDH1A1 (0.58) | NPC1POLBTBXAS1CYP19A1CYP11B1 | |
| SCHEMBL1024261 | 0.76 | CYP11B1 (0.84) | POLBTBXAS1CYP19A1CYP11B1CYP11B2 | |
| Benzylimidazole SCHEMBL16236718 | 0.76 | TBXAS1 (0.80) | POLBTBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL13006744 | 0.76 | CYP11B1 (0.69) | POLBTBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28716290 | 0.75 | CYP11B1 (0.59) | NPC1POLBTBXAS1CYP19A1CYP11B1 | |
| SCHEMBL18132582 | 0.75 | CYP19A1 (0.60) | NPC1POLBTBXAS1CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.75 | CYP11B1 (0.81) | POLBTBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10665912 | 0.75 | CYP19A1 (0.63) | TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | disclosed |
| CN-1033752-C | (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives | JANSSEN PHARMACEUTICA NV (SE) | 1997-01-08 | — | — | CN | disclosed |
| US-5441954-A | Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells | JANSSEN PHARMACEUTICA N. V. (BE) | 1995-08-15 | — | — | US | disclosed |
| CN-1106005-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| CN-1106004-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5268380-A | Therapy for keratinization in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-07 | — | — | US | disclosed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | disclosed |
| CN-1042912-A | (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-06-13 | — | — | CN | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |